The cheapest GLP-1 medication in May 2026 ranges from $25 a month to $1,086 a month for what is functionally the same drug. The spread depends on what insurance you have, what form of the molecule you’ll take, and whether the headline price you saw is actually the ongoing price.
Four floor numbers anchor the market right now:
- $25/month with commercial insurance covering Zepbound, Mounjaro, or Wegovy (manufacturer savings card)
- $50/month on Medicare starting July 1, 2026 (new CMS GLP-1 Bridge Program)
- $99/month for compounded semaglutide via telehealth (Trimi, annual prepay)
- $299/month for FDA-approved branded tirzepatide (LillyDirect Zepbound vials)
Most $99 headlines are not $99 once intro pricing ends, doses titrate, or membership fees kick in. MEDVi jumps from $179 to $299 after month one. Eden jumps from $149 to $249. Mochi’s $99 advertised rate becomes $148 to $178 once the mandatory membership lands. We’ll show you the real ongoing prices.
Below are eight legal pathways with verified May 2026 numbers. Commercially insured: skip to #1. Uninsured and want the floor: #2. FDA-approved and cheap: #5. Medicare: #8.
Top Picks Comparison Table
| Path | Best For | Starting Price | Patient-First Score | Apply Now |
|---|---|---|---|---|
| Manufacturer Savings Cards | $25 a Month if You’re Commercially Insured | $25/mo | — | — |
| Compounded Semaglutide via Telehealth | $99 to $249 a Month | $99/mo | — | — |
| Compounded Tirzepatide via Telehealth | $125 to $349 a Month | $125/mo | — | — |
| Microdosing | How Staying at a Lower Dose Cuts Your Cost by 30 to 50 Percent | $900/mo | — | — |
| LillyDirect Zepbound Vials | The Cheapest FDA-Approved Tirzepatide at $299 | $299/mo | — | — |
| Found | FDA-Approved GLP-1 Pills From $149 | $149/mo | 10 / 100 | See Offer |
| NovoCare Wegovy Cash Pay | $199 Intro, $349 Ongoing for Brand-Name Sema | $199/mo | — | — |
| Medicare GLP-1 Bridge Program | $50 a Month Starting July 1, 2026 | $50/mo | — | — |
1. Manufacturer Savings Cards: $25 a Month if You’re Commercially Insured
$25 a month is the cheapest legal price for a brand-name GLP-1 in the United States. It’s a copay, not a cash price, so it only works if you already have commercial insurance that covers Zepbound, Mounjaro, or Wegovy.
Eli Lilly runs the same $25 program for both Zepbound (obesity indication) and Mounjaro (type 2 diabetes indication). Novo Nordisk runs an equivalent $25 program for Wegovy. All three are valid through December 31, 2026, capped at $1,300 in savings per year across roughly 13 fills.
The reason most readers don’t know they qualify: “commercial insurance covering Zepbound” is a rare combination. Many commercial plans flat-out exclude weight-loss drugs. The savings card discounts the copay; it cannot force coverage. Step one: pull your formulary and search for “Zepbound,” “Mounjaro,” or “Wegovy” before applying for the card.
Federal anti-kickback rules block Medicare, Medicaid, TRICARE, VA, and DoD patients from using these cards. There is no workaround. On a government plan, this path is closed. Jump to #5 or #8.
Best for: Commercially insured readers whose plan already covers the drug.
Skip if: You’re on Medicare or Medicaid, or your plan excludes weight-loss drugs.
Quick check: Find your plan’s formulary PDF and search the drug name before applying.
2. Compounded Semaglutide via Telehealth: $99 to $249 a Month
For uninsured readers, this is the workhorse path and the most over-marketed category in the GLP-1 space. The verified May 2026 floor is $99/month at Trimi (flat rate at all doses, annual prepay required, $1,188 charged upfront). GobyMeds matches at $99 on starter bundle, $169 standard.
A few short-list providers and their honest angles:
- Trimi: $99/mo flat, all doses, annual prepay. Cheapest absolute floor. Minimal coaching.
- GobyMeds: $99 starter, $169 standard. Strong transparency. Higher doses climb.
- Eden Health: $149 first month, $249 ongoing. Flat-rate, month-to-month.
- Henry Meds: $297 month-to-month or roughly $197/mo on a 12-month prepay. Dose-based pricing during titration.
- MEDVi: $179 first month, $299 ongoing. FDA warning letter #721455 (February 20, 2026) for misbranding. Does not compound in-house.
- Mochi Health / MyStart: $99 medication plus a $49 to $79 mandatory membership. Real cost $148 to $178.
- Hims/Hers: $199 to $299. Novo Nordisk patent lawsuit (February 2026) and DOJ referral. Material mid-program risk.
- Embody: $199 month-to-month, $159/mo on a 6-month plan ($954 total).
- OnlineSemaglutide.org: $141/mo on a 6-month plan. Lowest verified multi-month ongoing rate in our research.
- Peak Wellness: $229 first month, $349 ongoing, or roughly $232/mo on a 6-month prepay ($1,396 total). Flat-rate, dose-independent.
Compare six-month total spend, not the month-one teaser. Trimi $99 flat = $594. OnlineSemaglutide.org $141 = $846. Eden flat = $1,394. Henry Meds prepay = ~$1,182. MEDVi = $1,674 once the intro month ends.
Flat-rate pricing matters once you titrate past 5 mg semaglutide. Dose-based providers can quietly add $50 to $100 a month as your prescriber escalates the dose, and most readers don’t catch the math until the third charge.
Best for flat-rate pricing: Trimi (cheapest absolute), Eden (no annual lock-in), or Peak Wellness on the 6-month plan if you want a service tier above bare-bones.
Best for month-to-month flexibility: Eden Health.
Skip: MEDVi (active FDA warning letter, doesn’t compound in-house) and Hims & Hers (Novo Nordisk litigation plus DOJ referral, real risk of mid-program disruption).
3. Compounded Tirzepatide via Telehealth: $125 to $349 a Month
For most of 2024 and 2025, compounded tirzepatide cost roughly double compounded semaglutide. That changed in late 2025. As of May 2026, the cheapest verified compounded tirz is $125 a month flat, against $99 for compounded sema. A $26 premium for the stronger drug.
Tirzepatide is a dual GLP-1 and GIP receptor agonist; semaglutide hits only the GLP-1 receptor. In SURMOUNT-1, tirzepatide produced larger average weight loss than semaglutide produced in STEP trials. If cost gets you within $30 a month of either drug, the clinical math usually favors tirzepatide.
Verified compounded tirzepatide pricing in May 2026:
- Trimi: $125/mo flat at all doses. Annual prepay. The cheap floor.
- GobyMeds: $299/mo starting; climbs to $399 to $499 at higher doses.
- Eden Health: $299 first month, $349 ongoing. Flat-rate (no dose hikes).
- Henry Meds: $299 to $349 range, dose-based.
- SkinnyRx: up to $349 across injectable and tablet formats.
- Peak Wellness: $229 first month, $349 ongoing, or $232/mo prepaid 6 months. Flat-rate.
The gap reopens above the floor. Trimi wins on absolute price. Flat-rate competitors like Eden and Peak Wellness win when you’d rather pay a premium to avoid annual prepay or dose-tier escalation.
Quick math: Trimi at $125/mo flat for 12 months = $1,500 total. Retail Zepbound pen at $1,086/mo = $13,032. An 88% cut for the same active molecule.
Skip if: You’re sensitive to GI side effects at the standard 5 to 7.5 mg range and would rather stay lower. The next section is for you.
4. Microdosing: How Staying at a Lower Dose Cuts Your Cost by 30 to 50 Percent
What if the cheapest GLP-1 plan isn’t a cheaper provider, but a lower dose of the one you already pay for?
Microdosing means holding at a lower maintenance dose (1 mg weekly semaglutide, or 2.5 to 5 mg tirzepatide) rather than titrating to the standard target (2.4 mg semaglutide or 15 mg tirzepatide). UNC researchers published a formal protocol description in Diabetes Care in early 2025. No randomized trials on microdosing exist yet, but case-series evidence supports adequate efficacy for moderate weight loss goals.
The economics depend on your pathway:
- Dose-based providers (Henry Meds, MEDVi, LillyDirect vials at 7.5 mg+): microdosing saves real dollars because you stay in the cheaper tier. Six months at 1 mg compounded semaglutide costs $900 to $1,500 versus $1,794 at LillyDirect full titration versus $6,516 retail.
- Flat-rate providers (Trimi, Eden, Peak Wellness): microdosing doesn’t change the bill, but it reduces side-effect burden and the friction of escalation.
A 2025 Journal of Managed Care & Specialty Pharmacy analysis found tirzepatide 15 mg was the most cost-efficient dose for patients targeting 30%+ body weight loss. For 10 to 15% goals, staying at 5 to 7.5 mg delivers strong results at a fraction of the cost.
How to ask: tell your prescriber you want a sub-titration protocol. Hold at your current dose (or step up in half-increments) once appetite suppression is adequate. Most async telehealth providers honor a documented patient preference if you raise it before the next titration window.
Best for: Readers with moderate weight loss goals, anyone with significant GI side effects at standard doses, anyone on a dose-based provider or LillyDirect vials.
Skip if: Your provider is already flat-rate, or you’re targeting 25%+ weight loss where higher doses are the cost-efficient path.
Caveat: No RCTs yet. Bring the strategy to your prescriber.
5. LillyDirect Zepbound Vials: The Cheapest FDA-Approved Tirzepatide at $299
The cheapest FDA-approved tirzepatide in the United States as of May 2026 is $299 a month, direct from Eli Lilly. It comes in a vial of freeze-dried powder you reconstitute yourself. It’s not as turn-key as a pen. It’s also $787 a month cheaper than one.
Verified Lilly Self Pay Journey Program pricing (February 23, 2026 update):
- 2.5 mg: $299/month
- 5 mg: $399/month
- 7.5 mg through 15 mg: $449/month flat (if you refill within 45 days of your last fill)
Miss the 45-day window and the higher doses jump to standard self-pay rates: 7.5 mg $599, 10 mg $699, 12.5 mg $849, 15 mg $1,049. Set a calendar reminder for day 30 of each fill to trigger your reorder.
The reconstitution piece is what trips people up. The vial contains lyophilized tirzepatide powder. You draw bacteriostatic water into a syringe, inject it into the vial, swirl gently, then draw your dose into an insulin syringe. The first time feels like high school chemistry. The fifteenth time it’s a habit. YouTube tutorials handle the visual training.
At $299/month, this is 72% cheaper than the retail Zepbound pen ($1,086/mo). Versus Trimi compounded tirz at $125 flat, you’re paying a $174/month premium for manufacturer-grade FDA-approved product with full quality control.
Best for: Self-pay readers who want FDA-approved branded medication, are comfortable reconstituting (or willing to learn), and can hit the 45-day refill cadence.
Skip if: You’d rather not handle powder and syringes. Compounded telehealth (#2 or #3) handles the pharmacy side for you.
6. Oral Wegovy and Foundayo: FDA-Approved GLP-1 Pills From $149
Two FDA-approved GLP-1 pills are available at $149 a month or less as of May 2026. A year ago neither existed at this price. If injections were the reason you’ve been waiting, that reason is gone.
Oral Wegovy (semaglutide tablet) via NovoCare cash-pay: $149/month for the 1.5 mg and 4 mg doses. The 4 mg limited offer expires August 31, 2026, then reverts to $199/month. Same active molecule as injectable Wegovy. Daily oral dosing instead of weekly injection.
Foundayo (orforglipron) via GoodRx: $149/month. Foundayo is the first FDA-approved oral small-molecule GLP-1, structurally different from semaglutide and tirzepatide. It’s also one of the three drugs covered by the July 2026 Medicare Bridge Program (see #8).
The trade-off: oral GLP-1 absorption is meaningfully lower and more food-timing-sensitive than injectable. You take the pill fasted, then wait 30 minutes before food or drink. Miss the window and absorption drops. Average weight loss with oral semaglutide is real but generally lower than injectable in head-to-head data.
Compounded sublingual drops and tablets exist (SkinnyRx and others) at similar price points, but they lack FDA approval and efficacy data. We don’t recommend them as a first oral option.
Best for: Needle-averse readers, anyone who can build a daily-pill habit, readers targeting moderate weight loss (10 to 15% body weight).
Skip if: You’re targeting 20%+ body weight loss. Injectable semaglutide and tirzepatide outperform oral options in most head-to-head trials.
Time-sensitive: Oral Wegovy 4 mg drops to $199/mo after August 31, 2026. If you’re already considering it, the next 14 weeks matter.
7. NovoCare Wegovy Cash Pay: $199 Intro, $349 Ongoing for Brand-Name Sema
Some readers don’t want Zepbound, compounded, or a pill. They want brand-name injectable Wegovy at a cash price that isn’t $1,400 a month. NovoCare’s cash-pay program is the answer.
Verified NovoCare injectable Wegovy pricing: $199/month for the first two months (the 0.25 mg and 0.5 mg intro titration doses), through June 30, 2026. After that, $349/month for standard maintenance doses. FDA-approved branded semaglutide in the familiar pre-filled pen.
At $349/month, this is the brand-name semaglutide cash floor. Versus alternatives:
- $349 NovoCare Wegovy (brand sema injectable) vs $449 LillyDirect Zepbound at the highest tier (brand tirz injectable) vs $1,086 retail Zepbound pen.
- $349 NovoCare Wegovy vs roughly $99 to $249 compounded semaglutide.
Use this path if you specifically want injectable brand-name semaglutide and you’re paying cash. If brand versus compounded doesn’t matter to you, #2 is roughly half the price. If FDA-approved branded matters but the specific molecule doesn’t, the LillyDirect Zepbound vial (#5) is cheaper and tirzepatide tends to outperform semaglutide on average weight loss.
8. Medicare GLP-1 Bridge Program: $50 a Month Starting July 1, 2026
Until July 1, 2026, Medicare covers GLP-1 weight-loss drugs for almost no one. Starting July 1, that changes. The Medicare GLP-1 Bridge Program is a CMS pilot offering eligible Part D enrollees a $50/month copay on weight-loss GLP-1s. The program runs through December 31, 2027, with a possible permanent program in 2028.
Covered drugs:
- Wegovy injection
- Wegovy tablet (oral)
- Zepbound KwikPen
- Foundayo (orforglipron)
Eligibility:
- Enrolled in a Medicare Part D plan
- BMI of 27 or higher
- At least one qualifying condition (heart disease, prediabetes, hypertension, sleep apnea, dyslipidemia)
- Prior authorization required
The wrinkle most coverage misses: the Bridge runs on a separate central pathway processed by CMS contractor Humana, not your standard Part D plan. Your existing formulary does not automatically cover Bridge drugs. You (or your prescriber) submit prior auth through Humana directly.
How to access it:
- Confirm your Medicare Part D enrollment is active.
- Confirm BMI 27+ and at least one qualifying condition.
- Have your prescriber submit prior auth through CMS/Humana (not your Part D plan).
- Pick from Wegovy injection, Wegovy tablet, Zepbound KwikPen, or Foundayo.
- Pay $50/month at the pharmacy.
Best for: Medicare Part D enrollees with BMI 27+ and at least one qualifying condition.
Skip if: You’re not on Medicare. Federal rules block you from this path and from the $25 savings cards. Look at #2 (compounded) or #5 (LillyDirect) instead.
Frequently Asked Questions
What’s the absolute cheapest GLP-1 in May 2026?
Four floor numbers, depending on your insurance: $25/month with commercial insurance (manufacturer savings card on Zepbound, Mounjaro, or Wegovy). $50/month on Medicare starting July 1, 2026 (CMS GLP-1 Bridge). $99/month compounded semaglutide (Trimi annual prepay). $299/month FDA-approved branded tirzepatide (LillyDirect Zepbound vials). Pick the row that matches your situation.
Is compounded semaglutide safe, and is it even still legal?
503A pharmacy compounding of semaglutide and tirzepatide remains legal in May 2026, but only for patients with a documented individualized medical need (allergy to an inactive ingredient, specific dosing requirement). FDA’s April 30, 2026 proposal would remove both drugs from the 503B Bulks List. If finalized after the June 29, 2026 comment period, large-scale 503B compounding ends, though 503A pharmacy access likely continues. Choose providers with PCAB accreditation, LegitScript certification, and no active FDA warning letters.
Does cheap mean less effective?
The active ingredient is the same molecule whether compounded or branded. Efficacy difference comes from quality control, not the drug itself. The FDA logged 545 adverse-event reports linked to compounded tirzepatide through July 2025, which is material but small relative to total volume. Brand-name FDA approval guarantees consistency batch to batch; compounded varies by pharmacy. Pick by pharmacy track record (accreditations, warning-letter history, complaint patterns), not by lowest headline price alone.
Can I use HSA or FSA money for compounded GLP-1?
Yes. Compounded semaglutide or tirzepatide from a licensed pharmacy is HSA/FSA eligible when prescribed for a documented medical condition (obesity, type 2 diabetes, insulin resistance). Some plan administrators ask for a Letter of Medical Necessity. Pre-tax dollars effectively discount your spend 20 to 35% depending on your tax bracket. At $250/month ($3,000/year), that’s $600 to $1,050 back annually. 2026 HSA limits: $4,300 individual, $8,550 family.
What happens when my $99 intro pricing ends?
Most $99 headlines are not $99 ongoing. MEDVi: $179 first month, $299 thereafter. Eden: $149, then $249. Mochi: $99 medication plus $49 to $79 mandatory membership, real cost $148 to $178. Trimi holds at $99, but only with annual prepay billed upfront. Compare six-month total spend, not month-one. Read auto-renewal terms and confirm you can cancel online with at least a 72-hour window before billing.
I’m uninsured and needle-averse. What’s actually my best option?
Two FDA-approved oral GLP-1s sit at $149/month. Oral Wegovy (semaglutide tablet) via NovoCare at $149/month for the 1.5 mg and 4 mg doses through August 31, 2026, then $199/month. Foundayo (orforglipron) via GoodRx at $149/month. Both require fasted dosing with a 30-minute wait before food or drink. Efficacy is lower than injectable but real for moderate weight loss goals. Compounded sublingual drops exist at similar prices but lack FDA approval and efficacy data.